MSNs-loaded HMME and Erastin-mediated ferroptosis combined with sonodynamic therapy for HCC treatment [0.03%]
负载MSN的HMME和艾拉司汀介导的铁死亡结合声动力疗法治疗肝细胞癌
Chang Zhao,Guchun Qin,Caixia Ling et al.
Chang Zhao et al.
Background: Ferroptosis can have a major impact on the development and advancement of hepatocellular carcinoma (HCC) due to its clear association with heightened vulnerability to the disease. This study aimed to develop a...
Neoadjuvant therapy for hepatocellular carcinoma-priming precision innovations to transform HCC treatment [0.03%]
肝细胞癌的新辅助治疗-精准创新以转变HCC的治疗方式
Kristin E Goodsell,Alice J Tao,James O Park
Kristin E Goodsell
Hepatocellular carcinoma (HCC) is increasing in prevalence globally, and cure remains limited with non-operative treatment. Surgical intervention, through resection or transplantation, offers a potential for cure for select patients. Howeve...
Nutrient transporter-oriented nanoinhibitor counteracts intracellular metabolic reprogramming for RT-resistant HCC treatment [0.03%]
以营养转运体为导向的纳米抑制剂通过抗衡细胞内代谢重编程来对抗RT耐药性的HCC治疗
Yuehua Wang,Zhenjie Wang,Mengnan Liu et al.
Yuehua Wang et al.
Radiotherapy (RT) is the primary treatment modality for hepatocellular carcinoma (HCC). Inevitably, the X-ray exposure also increases the metabolic stress and energy demands in surviving tumor cells, which leads to metabolic reprogramming t...
Targeting autophagy in HCC treatment: exploiting the CD147 internalization pathway [0.03%]
靶向肝癌治疗中的自噬：利用CD147内吞途径
Meirui Qian,Ziyu Wan,Xue Liang et al.
Meirui Qian et al.
Background/aims: Chemotherapy resistance in liver cancer is a major clinical issue, with CD147 playing a vital role in this process. However, the specific mechanisms underlying these processes remain largely unknown. This...
FTO/m6A/GPNMB axis: a novel promising target for hepatocellular carcinoma (HCC) treatment? [0.03%]
FTO/m6A/GPNMB轴：肝细胞癌治疗的新靶点？
Bernd Heinrich,Francisco Javier Cubero
Bernd Heinrich
Development and validation of a biomarker index for HCC treatment response [0.03%]
用于肝癌治疗反应的生物标志物指数的开发和验证
Jeff Liang,Po-Yi Li,Joshua Norman et al.
Jeff Liang et al.
Background: Serum AFP-L3%, AFP, and DCP are useful biomarkers for HCC detection, but their utility in assessing treatment response remains unknown. We aim to evaluate the accuracy of a biomarker model in the detection of ...
Samuel D Butensky,Kevin G Billingsley,Sajid A Khan
Samuel D Butensky
BCG as an Innovative Option for HCC Treatment: Repurposing and Mechanistic Insights [0.03%]
BCG作为HCC治疗的创新选择：药物新用及机制研究
Farzam Vaziri,Tahereh Setayesh,Ying Hu et al.
Farzam Vaziri et al.
This study investigates Bacillus Calmette-Guérin (BCG) as a potential treatment for hepatocellular carcinoma (HCC), a condition often associated with unfavorable treatment outcomes. Exploiting BCG's recognized immune-boosting properties, p...
Revolutionizing HCC Treatment: A Promising Multimodal Approach With TACE, SBRT, and Immunotherapy [0.03%]
多模式治疗肝细胞癌的革命：TACE、SBRT和免疫疗法的前景广阔
Ashish Kumar,Anil Arora,Praveen Sharma
Ashish Kumar
Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment [0.03%]
通过 neo抗原mRNA疫苗提高ICIs对肝癌治疗的效率
Rui Han,Yuqian Wang,Lingeng Lu
Rui Han
This study builds upon the groundbreaking mRNA vaccine Nobel Prize win in 2023 for COVID-19 prevention, paving the way for next-generation mRNA cancer vaccines to revolutionize immunotherapy. Despite the existing challenges, such as the pre...
耗时 0.10646 秒，为您在
48229835
条记录里面共找到 32 篇文章 [XML]